
There's a Lesson to Learn From Daniel Kahneman's Death
In explanation, Professor Kahneman included a letter that his friends would receive a few days later. 'I have believed since I was a teenager,' he wrote, 'that the miseries and indignities of the last years of life are superfluous, and I am acting on that belief. I am still active, enjoying many things in life (except the daily news) and will die a happy man. But my kidneys are on their last legs, the frequency of mental lapses is increasing, and I am 90 years old. It is time to go.'
Some of those he loved, he added, had tried to persuade him to wait until it was obvious that his life was not worth extending, but they had, reluctantly, come around to supporting his choice.
We did not try to dissuade Professor Kahneman, but we asked him to view the interview as a final opportunity to tell people what he thought they should know about living well. He accepted the invitation, though he did not wish to discuss his decision to end his life.
The interview took place on March 23. Professor Kahneman was cheerful and lively, with no mental lapses. He wrote to us the next day to say that he had greatly enjoyed the conversation. We did not hear from him again. He died, as he had planned, on March 27.
The announcements of Professor Kahneman's death at the time did not reveal how or where he died. Now that those facts have been reported, we feel comfortable discussing the important issues raised by his choice to end his life.
Many countries and 10 U.S. states allow voluntary assisted dying for those who are terminally ill. In some jurisdictions, assistance is also permitted for those who have an incurable condition that causes them unbearable suffering. But allowing relatively healthy people to end their lives because they see their lives as completed is more controversial. Professor Kahneman traveled to Switzerland because it allows competent adults with a firm wish to die to legally receive assistance in dying, whether or not they are residents.
At 90, Professor Kahneman thought that he had completed his life. Long associated with Princeton University, he had certainly accomplished a great deal. In the 1970s he helped to pioneer the field of behavioral economics, contributing to our understanding of human decision making. His 2011 book, 'Thinking, Fast and Slow,' was an international best seller.
But despite his advanced age, he was still capable of research and writing and could still enlighten audiences on how to make better decisions. Apart from his intellectual gifts, he was healthy enough to participate in friendship and family life. Why did none of this give him sufficient reason to continue to live?
The answer, we believe, can be found toward the end of the interview we did with him. He surprised us by denying that his work had any objective significance. 'Other people happen to respect it and say that this is for the benefit of humanity,' he said. 'I just like to get up in the morning because I like the work.'
We pushed back, arguing that there are objectively good things to do with one's life. But he resisted. 'I feel I've lived my life well,' he said, 'but it's a feeling. I'm just reasonably happy with what I've done. I would say if there is an objective point of view, then I'm totally irrelevant to it. If you look at the universe and the complexity of the universe, what I do with my day cannot be relevant.'
We do not agree that the size and complexity of the universe render irrelevant an individual's work for the benefit of humanity. But if, after careful reflection, you decide that your life is complete and remain firmly of that view for some time, you are the best judge of what is good for you. This is especially clear in the case of people who are at an age at which they cannot hope for improvement in their quality of life.
There are serious grounds for opposing such an extension of the right to die. Perhaps some older people who say that they are tired of living would feel more positive about their lives if they received psychological counseling. Perhaps doctors should not be involved in such a procedure, since the patient is not receiving treatment for a terminal medical condition. Perhaps, if it becomes normal for older people to request and receive assisted dying when they are not terminally or incurably ill, many who believe that they are a burden on their family will feel pressure to end their lives.
All these objections can be met. It should be obligatory for those who make a request for assistance in dying to first receive psychological counseling. As for the participation of doctors, in many countries the reason they are involved is that the patient has to have a serious medical condition and generally only doctors can prescribe the drugs used and sign the death certificate. But a new professional specialty could be developed for assisting people to die when they do not have a serious medical condition.
We do not deny that a belief about being a burden on family may be a reason for some older people to choose to end their lives, but one should not assume that it is typically the principal reason. In Oregon, where assisted dying is legal, the state annually reviews cases that comply with the legislation: Feeling like a burden was a concern for 42 percent of the terminally ill patients who died by physician-assisted suicide last year but was less significant than losing autonomy (a concern for 89 percent), being less able to engage in activities that make life enjoyable (88 percent) and loss of dignity (64 percent). Nor is it unreasonable for people whose quality of life has declined to a level that is only marginally positive to take into account whether they are a burden to those they love.
Professor Kahneman signaled concern that if he did not end his life when he was clearly mentally competent, he could lose control over the remainder of it and live and die with needless 'miseries and indignities.' One lesson to learn from his death is that if we are to live well to the end, we need to be able to freely discuss when a life is complete, without shame or taboo. Such a discussion may help people to know what they really want. We may regret their decisions, but we should respect their choices and allow them to end their lives with dignity.
If you are having thoughts of suicide, call or text 988 to reach the National Suicide Prevention Lifeline or go to SpeakingOfSuicide.com/resources for a list of additional resources.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Geek Wire
a day ago
- Geek Wire
UW researchers discover AI-powered breakthrough that could boost precision cancer treatment
The co-lead authors of a study publishing today in Science describing AI-designed proteins for target health theraphies, from left: Julia Bonzanini, Nathan Greenwood and Bingxu Liu. All are researchers with UW Medicine's Institute for Protein Design. (IPD Photo) A breakthrough in the science used to customize the treatment of cancer and other diseases is so promising that researchers at the University of Washington are planning to launch a company to commercialize the technology. The strategy uses artificial intelligence to create proteins that recognize and bind to specific markers on diseased cells, creating what are essentially biological neon signs that attract immune cells to destroy the targets. The research comes from the lab of Nobel laureate David Baker and UW Medicine's Institute for Protein Design, which Baker leads, and is being published today in the journal Science. Additional study authors come from multiple UW departments, the Garcia Lab at Stanford University, and the Scheinberg Lab at Memorial Sloan Kettering Cancer Center. 'Detecting unhealthy cells is one of the main jobs of the immune system, but it doesn't always notice the subtle signs of cancer or viral infection,' Baker said in a statement. 'In this study, we show that computer-designed proteins can help human immune cells spot the right targets and function more effectively.' The work could lead to significant advancements in precision immunotherapy, which delivers disease-fighting drugs that are crafted for individual patients. The key to this personalized approach lies in understanding how cells display their identity on their surfaces. The outside membrane of a cell is studded with molecules that include small proteins called peptides that reveal a cell's inner workings, including if it's cancerous or infected by a virus such as HIV. The scientists used RFdiffusion and ProteinMPNN — AI-tools built by the Institute for Protein Design — to efficiently and cheaply engineer proteins that recognize the unique peptides. University of Washington biochemist and Nobel Prize laureate David Baker at his office in Seattle. (GeekWire Photo / Lisa Stiffler) The custom-made proteins can then be integrated into chimeric antigen receptors (CARs), which are engineered molecules that attract and activate immune-system warriors called T cells to attack specific targets. In their study, the researchers designed proteins for 11 peptide targets and eight successfully triggered a T-cell response. Of those eight, two produced such a strong immune response that the T cells killed the targeted cells. The peptide targets included HIV fragments and tumor-related protein mutations. 'We've shown how advances in protein design could make personalized cancer therapy possible, and we intend to start a company to turn these results into real therapies that benefit patients,' said Bingxu Liu, co-lead author of the study and postdoctoral scholar in the Baker Lab. Since 2014, the Institute for Protein Design has spun off 10 startups, and Baker has co-founded 21 tech companies. When Baker won the Nobel Prize in October, the Royal Swedish Academy of Sciences noted that 'his research group has produced one imaginative protein creation after another, including proteins that can be used as pharmaceuticals, vaccines, nanomaterials and tiny sensors.' The researchers involved in the latest study explained that the strategy can be easily adapted to new scenarios. Within days, the team was able to take one of its successful proteins and use AI to modify it to target new cancer and virus-associated peptides. The process could make it much cheaper to create personalized treatments. 'I'm hopeful that this will lead to new therapies that are more accessible to patients around the world who do not benefit from current state-of-the-art cancer treatments,' said Julia Bonzanini, a co-lead author and Baker Lab graduate student. Researchers worldwide can access online the open-source software used in the research. Other authors of the Science paper, titled 'Design of high-specificity binders for peptide–MHC-I complexes,' are Nathan Greenwood, Amir Motmaen, Jeremy Meyerberg, Tao Dao, Xinyu Xiang, Russell Ault, Jazmin Sharp, Chunyu Wang, Gian Marco Visani, Dionne Vafeados, Nicole Roullier, Armita Nourmohammad, David Scheinberg and Christopher Garcia. RELATED:


Forbes
a day ago
- Forbes
Chan Zuckerberg Initiative Introduces New GREmLN Model For Genetics
3D illustration of a DNA molecule with sparkling effects symbolizing complexity and genetic ... More diversity. Futuristic concept of genomics, precision medicine, and computational life sciences. If you've been paying attention to modern research and AI, you know that genetics is a major application of this technology to our lives. Alphafold, for which its founders received a Nobel prize in science, is a major example, but it's just the tip of the iceberg when it comes to what AI is doing in healthcare, and in genetics in particular. This month we have a new announcement from the Chan Zuckerberg Initiative backed by Mark Zuckerberg and Melissa Chan that contemplates a brand new system called GREmLN (Gene Regulatory Embedding-based Large Neural model) for identifying cellular behavior. It may help with cancer research and work on other diseases. Part of the project involves an imaging technique, and assistance in developing software for scientists. There's also what CZ calls a 'single cell data set' of 1 billion cells, developed with 10X Genomics and Ultima Genomics. From reading documentation, it sounds like what this means is that teams assembled data on no less than a billion cells, in order to build a collective model of what an average cell would look like and how it would function. The new model, scientists suggest, can help to characterize genetic drivers of disease, and find new ways to restore diseased cells to health. Four Major Goals and Challenges Amongst the announcement of this ground-breaking resource, spokespersons at CZ identify four broader objectives scientists are reaching for: One involves building an AI-based virtual cell model – which GREmLN is presumably instrumental in. Another is 'developing novel imaging technology to map, measure and model complex systems,' which sounds like a similar type of exercise. Reportedly, the teams also hope to figure out how to directly sense inflammation in the body, and to harness the human immune system for various kinds of immunotherapy. Parsing these objectives further, you can see how the new GREmLN model will drive research on what the CZ Institute calls 'molecular logic' or the study of how parts of a cell interact or work together. What are Biohubs? A press release from Chan Zuckerberg also mentions the creation of Biohubs as laboratories fueling collaborative development, or, in the words of spokespersons, 'cross-disciplinary research institutions.' ChatGPT provides a definition of a Biohub, and points out that the Chan Zuckerberg Biohubs are not the same as a series of Biohubs developed by the World Health Organization. 'Biohubs are collaborative research centers designed to accelerate breakthroughs in biomedical science by fostering interdisciplinary cooperation, sharing resources, and facilitating innovation,' the model notes. 'Typically established through partnerships between universities, research institutions, healthcare providers, government agencies, and industry leaders, Biohubs aim to address complex biological and medical challenges by combining expertise across biology, medicine, engineering, computing, and data science. … Prominent examples include the Chan Zuckerberg Biohub, which unites Stanford, UCSF, and UC Berkeley researchers to tackle infectious diseases and advance biomedical knowledge through open science.' Of the WHO Biohubs: 'A totally separate WHO initiative aimed at sharing biological materials (like virus samples with pandemic potential) among member states… So, while (CZ Biohubs and WHO Biohubs) share the 'Biohub' name, their missions, governance, and affiliations are entirely distinct.' The concept, however, is the same – scientists are banding together to do more innovative work on cell structure, for example, in nucleus and mitochondria DNA. A little research shows some of the distinctions between different types of DNA present in a cell. A lot of the DNA is isolated in the nucleus of the cell, but there's also mitochondria, less attached to that central cluster. Literature Weighs In Fans of Madeleine L'Engle's youth fiction in the 1980s will note that her work explored the idea of subcellular entities and their impact on macroscopic systems. Just for fun. I ask ChatGPT about L'Engle's impact on modern cellular and genomic research. 'Madeleine L'Engle's work didn't explicitly prefigure specific contemporary research into genetics or mitochondria, but her writing, particularly A Wrinkle in Time (1962), A Wind in the Door (1973), and the rest of her Time Quintet, did anticipate broad scientific and philosophical themes related to cellular biology, mitochondrial function, interconnectedness, and universal harmony,' the model said. 'In A Wind in the Door, for instance, L'Engle explores the concept of 'farandolae,' fictional microscopic entities within mitochondria, whose harmony or disharmony directly affects the health of living organisms and even the universe. Her vision captured a holistic view of biology, recognizing mitochondria as fundamental life engines, long before mainstream science widely emphasized mitochondria's central role in health, aging, and diseases.' How many readers remember the farandolae, which L'Engle characterized in promoting a kind of social symbiosis that was a more prominent idea in a less data-driven age? 'The young farandolae cannot fill an adult role, so they maintain a parasitic existence on the adult farae,' writes a poster on Literature Stack Exchange, where human readers get together to ruminate on different aspects of a text. 'In fact, so long as they are under the influence of the Echthroi, they revel in their parasitism. It is all taking and no giving…' In any case, ChatGPT provides this summary: 'Though not predictive in a literal scientific sense, L'Engle's imaginative storytelling prefigured ideas in modern genetics and mitochondrial research—particularly notions of cellular symbiosis, bioenergetics, systemic interconnectedness, and the vital relationship between microscopic structures and macrocosmic health.' Driving Further Change It's easy to see how these partnerships will allow scientists to work more proactively on disease solutions. I thought this news was worth covering as we move through a banner year for artificial intelligence in healthcare. We are finding use cases everywhere, from diagnosis, to scheduling, to the kinds of research that support these clinical solutions. That's a feather in AI's cap. However, we just might still have a place for the philosophical, sometimes fictional portrayal of such systems, as in L'Engle's work that leans more into the speculative than the technical approach. What do you think?


Los Angeles Times
18-07-2025
- Los Angeles Times
How Growth Factors Are Transforming Anti-Aging Skincare
LA Times Studios may earn commission from purchases made through our links. If you continually chase every so-called 'miracle' ingredient (retinol, vitamin C, hyaluronic acid), you're not alone. Beauty culture is always a few steps ahead, but even the most wellness-savvy among us are tiring of surface-level promises. Now, a new approach is cutting through the noise: regenerative skincare, powered by growth factors. Unlike fleeting TikTok trends, growth factors (especially EGF) were first discovered by Nobel laureates, not influencers. These proteins act as cellular text messages, telling your skin when it's time to repair and renew. Our bodies make less of them as we is why, post-40, you notice more slack, dullness, and fine lines. Let's break down what makes growth factors, especially EGF (epidermal growth factor), so promising in anti-aging skincare. Growth factors are naturally occurring proteins that act as the body's 'repair signal,' binding to receptors on the surface of skin cells to stimulate renewal and ramp up collagen production. What sets EGF apart from typical hydrating ingredients? Instead of just working on the outermost layer, these proteins encourage cellular repair at a deeper level, which can help offset the visible effects of aging and support firmer, more resilient skin over time. Recent studies have shown that topical EGF can enhance skin elasticity and accelerate wound healing, which is why you'll now find it alongside other advanced actives like peptides. Palmitoyl Tripeptide-5, for example, is known to signal collagen renewal, while or its ability to relax expression lines. This new generation of formulas often layers growth factors with probiotic complexes to support the skin barrier and plant-based alternatives like bakuchiol, which provides the benefits of retinol without irritation or flaking. The result: serums that are less about immediate plumping and more about long-term resilience, helping skin recover from UV exposure, pollution, or even travel-induced dehydration. While the 'regenerative' category sounds clinical, there's a reason for that. These products draw on advances in cell biology and dermatology, echoing research showing that consistent use of growth factor-rich skincare can improve firmness and texture, making it one of the most evidence-backed strategies for supporting healthy, younger-looking skin at home. When it comes to skincare, time is a luxury. For educated, time-strapped adults who want streamlined routines without compromising on results, brands like MUMUK are leading the charge with smarter solutions. Instead of juggling a dozen products, more people are anchoring their routines with targeted growth factor serums (especially after sun exposure or stressful weeks) to help skin recover quickly and keep that balanced, healthy glow. It's easy to see why these bounce-back formulas are earning loyalty, especially among those who value both performance and simplicity. As MUMUK founder Stephanie Sprayregen puts it, 'Aging doesn't have to be something to fear. When we support the skin's natural ability to regenerate, we're not chasing youth, we're embracing renewal at every stage of life.' Curious about trying growth factors in your own routine? Here are a few science-backed serums worth trying. Bioeffect EGF Serum: This cult-favorite from Iceland uses barley-derived EGF for deep hydration and a firmer look. Skincare minimalists and pros alike love this ultra-light formula. Neocutis Lumière Firm Riche Extra Moisturizing Illuminating & Tightening Eye Cream: Growth factors aren't just for your face—this dermatologist-developed eye cream features a proprietary peptide and growth factor blend to smooth, hydrate, and depuff the delicate under-eye area. Shop Neocutis Lumière Firm Riche Eye Cream MUMUK Regenerative Complex Cell Renewal Serum: Packed with 5% bioengineered EGF and an advanced peptide-antioxidant blend, this minimalist serum delivers collagen support and barrier repair in one daily step. SkinMedica TNS Advanced+ Serum: This powerhouse serum contains a growth factor cocktail along with botanicals and peptides for full-spectrum anti-aging. If you want results and don't mind the splurge, this one is a derm-favorite. Let's get honest about limits. Growth factors aren't a magic wand. They can't 'lift' sagging skin like a surgeon, or erase decades in a week. If your skin barrier is badly compromised or if you're dealing with deep, structural sagging, you may still need professional intervention. And, if you have a history of cancer or are immunocompromised, consult your dermatologist before adding EGF to your routine. The real beauty of this new science-backed approach is that it isn't about extremes. It's about supporting skin as it changes, restoring what time and stress take, not fighting against nature. Click here to learn more about MUMUK